Comparing European and Japanese methods for examining colon cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to compare the diagnostic accuracy of the European and Japanese pathological investigation methods for colon cancer. The European approach relies primarily on pathologists without surgical involvement, while the Japanese method includes surgeons in the evaluation process. The study will assess whether the Japanese method is less accurate than the European method, which has not been systematically evaluated in the literature. Patients diagnosed with colon cancer who have undergone colectomy will be included in the trial.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients diagnosed with colon cancer who underwent colectomy;
* Patients with pathological confirmed adenocarcinoma;
* Patients agreed to participate in the study.

Exclusion Criteria:

* Patients suffered from rectal cancer;
* Patients diagnosed with colon cancer but did not undergo colectomy;
* Patients refused participation.

Where it's running

• Clinic of coloproctology and minimally invasive surgery
  Moscow, Russia Recruiting

Study contacts

• Principal investigator: Vladimir Balaban — Sechenov University
• Study coordinator: Mingze He
• Email: hemingze97@gmail.com
• Phone: +79801881266

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Laparoscopic vs Open Surgery for Colon Cancer in Patients with Visceral Obesity

  This study tests whether laparoscopic or open surgery leads to different long-term outcomes for adults with colon cancer and visceral obesity.

  Recruiting Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT07314996

• Improving mailed FIT screening in Appalachia

  This project will test whether changing the FIT kit materials and using phone versus text message navigation can help more average-risk adults in Appalachian counties complete colorectal cancer screening when they're overdue.

  Recruiting Ohio State University Comprehensive Cancer Center · Columbus, Ohio · NCT07173985

• Anti-mesothelin TNhYP218 CAR T cell therapy for mesothelin-expressing solid tumors

  This treatment will test whether a person's own engineered CAR T cells that target mesothelin can help adults with mesothelin-expressing solid tumors, including mesothelioma, that have returned or spread after standard therapy.

  Recruiting Phase 1 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT06885697

• Using AI to Improve Cost-Effectiveness of Colonoscopy Screening

  This study is testing whether using artificial intelligence during colonoscopies can help doctors tell the difference between harmful and harmless polyps, making screening for colon cancer more effective and affordable.

  Recruiting at 2 sites Istituto Clinico Humanitas · Rozzano, Milano and 1 other locations · NCT06041945

• Platform program for evaluating treatments in metastatic HER2-positive breast cancer

  This study is testing different new treatments for people with advanced HER2-positive breast cancer to see which ones work best before moving them to larger trials.

  Recruiting at 5 sites Phase 1/2 QuantumLeap Healthcare Collaborative · Birmingham, Alabama and 9 other locations · NCT05868226

• Evaluating dostarlimab for resectable colon cancer

  This study is testing if adding a new immunotherapy called dostarlimab to standard chemotherapy can help people with certain types of resectable colon cancer do better.

  Recruiting at 229 sites Phase 3 GlaxoSmithKline · Tucson, Arizona and 265 other locations · NCT05855200

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.